MESOBLAST LTD (MESO) Form 6-K — Oct 13, 2026
Mesoblast's FY2026 annual report (fiscal year ended June 30, 2026) shows the company's transition to commercial stage, with total revenue of US$120.3 million versus US$17.2 million in FY2025, driven by US$115.2 million of first-full-year net product sales for RYONCIL, its FDA-approved therapy for pediatric steroid-refractory acute graft-versus-host disease. Profitability is improving but not yet achieved: gross profit reached approximately US$104 million and net operating cash spend fell to US$43.8 million (US$13.4 million in H2), yet the company still posted a US$57.5 million net loss and holds US$102.9 million in cash against US$1,068.4 million of accumulated losses.
Key figures
- Revenue
- 120300000
- Debt Amount
- 125000000
- Revenue Yoy
- US$120.3 million FY2026 vs US$17.2 million FY2025 (~600% growth)
- Cash Position
- 102900000
- Maturity Date
- December 2030 (interest-only period)
- Shares Outstanding
- 1296862776
- Gross profit fy2026
- approximately US$104 million
- Usd denominated cash
- approximately 98%
- Credit facility tranches
- ["$75.0 million December 2025","$50.0 million June 2026"]
- Treatment centers onboarded
- more than 50
- Clbp phase3 patients treated
- 350
- Net operating cash spend fy2026
- US$43.8 million (H2: US$13.4 million; prior year: US$50.0 million)
- Ryoncil net product sales fy2026
- US$115.2 million
- Accumulated losses since inception
- US$1,068.4 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.